Age-Stratified Seroprevalence of Cytomegalovirus and Epstein–Barr Virus in a Population-Based Cohort in Japan, 2017–2024
Abstract Background Cytomegalovirus (CMV) and Epstein–Barr virus (EBV) are ubiquitous latent herpes viruses, but contemporary population-based seroprevalence data in Japan remain limited, particularly in younger age groups. This study aimed to characterize age- and sex-specific CMV and EBV seroprevalence in a population-based Japanese cohort and to describe combined serostatus patterns across age groups. Methods We conducted a cross-sectional seroepidemiological analysis of the Tohoku Medical Megabank Project Birth and Three-Generation (TMM BirThree) cohort. Serum samples collected between 2017 and 2024 were tested for CMV IgG (age 4–40 years; n = 2,247) and EBV viral capsid antigen IgG (age 4–30 years; n = 1,647) using commercial ELISA. Seroprevalence was stratified by age and sex. Combined CMV/EBV serostatus patterns were described, and sensitivity analyses assessed temporal consistency and intra-family clustering. Results CMV seroprevalence increased during childhood and adolescence and plateaued at approximately 70–80% in early adulthood, whereas EBV seroprevalence rose steadily, exceeding 70% in late adolescence and 90% in the late 20s, with minimal sex differences. Dual seropositivity increased with age, the CMV−/EBV− group declined, and CMV−/EBV+ remained more common than CMV+/EBV− across all age groups. These patterns were consistent in sensitivity analyses. Conclusions CMV and EBV exhibit distinct age-related seroepidemiologic patterns in Japan despite overlapping transmission routes. The early plateau of CMV seroprevalence and near-universal EBV seropositivity by young adulthood indicate divergent infection dynamics with implications for congenital CMV prevention, infectious mononucleosis risk, and ongoing vaccine strategy.
Authors
- Taku Obara (ORCID: https://orcid.org/0000-0002-3674-1674)
- Kazuki Kumada (ORCID: https://orcid.org/0000-0002-2970-7742)
- John D Diaz-Decaro (ORCID: https://orcid.org/0000-0001-6487-2113)
- Atsushi Hozawa (ORCID: https://orcid.org/0000-0002-8031-8523)
- Eiichi N. Kodama (ORCID: https://orcid.org/0000-0002-6622-2752)
- Anita Iyer
- Susan A. Hall (ORCID: https://orcid.org/0000-0002-5378-8562)
- STEFFI NAOMI
- Osamu Kogawara
- Soichi Ogishima (ORCID: https://orcid.org/0000-0001-8613-2562)
- Katja Engelberg
- Hisaaki Kudo (ORCID: https://orcid.org/0000-0002-4477-7095)
- Kumi Kawaji
- Mami Ishikuro (ORCID: https://orcid.org/0000-0002-2884-0023)
- Masatsugu Orui (ORCID: https://orcid.org/0000-0002-4871-8455)
- Shinichi Kuriyama (ORCID: https://orcid.org/0000-0002-6445-0911)
- Naoki Nakaya (ORCID: https://orcid.org/0000-0002-1467-161X)
- Masayuki P. Yamamoto (ORCID: https://orcid.org/0000-0002-9073-9436)
- Laura H. Hendrix
- Enejda Senko
- Kenichi Noguchi
Institutions
- Tohoku University (JP)
- Moderna Therapeutics (United States) (US)
- Tohoku Medical Megabank Organization (JP)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2026-11-04
- DOI
- https://doi.org/10.1093/ofid/ofag678
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00